Ofatumumab |
| Catalog No.GC65498 |
L'ofatumumab (Arzerra) est un anticorps monoclonal anti-CD20 entièrement humain qui induit une cytotoxicité À médiation cellulaire dépendante des anticorps et une cytotoxicité dépendante du complément dans les lymphocytes B exprimant le CD20.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 679818-59-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Ofatumumab (Arzerra) is a fully human anti-CD20 monoclonal antibody that induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity in CD20-expressing B lymphocytes[1].
[1]. Sanford M, McCormack PL. Ofatumumab. Drugs. 2010;70(8):1013-1019.
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *